Physician profile
Kamran Shahid
NPI 1336370642
$154,780.32
in general payments reported to CMS, 2019-2025
39 companies · $56K in 2025
The $56K reported for 2025 was more than what 97% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $458 · 2020: $174 · 2021: $403 · 2022: $1,101 · 2023: $27K · 2024: $69K · 2025: $56K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $124K · Travel and Lodging: $24K · Food and Beverage: $4,629.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $123,550.00 |
| Travel and Lodging | $24,466.51 |
| Food and Beverage | $4,628.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $151,158.09 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Novartis Pharmaceuticals Corporation | $507.88 | 2021-2025 | |
| Genentech USA, INC. | $451.37 | 2019-2025 | Tecentriq, Lunsumio, Polivy |
| Amgen INC. | $436.74 | 2019-2023 | Nplate, Vectibix, Xgeva |
| Astrazeneca Pharmaceuticals Lp | $269.14 | 2021-2025 | Imfinzi, Lynparza |
| Celgene Corporation | $159.89 | 2019-2024 | Reblozyl |
| Pfizer INC. | $151.61 | 2022-2025 | |
| Janssen Biotech, INC. | $143.98 | 2021-2024 | Darzalex, Imbruvica |
| Glaxosmithkline, LLC. | $129.20 | 2022-2025 | Blenrep, Ojjaara, Jemperli |
| Beigene USA, INC. | $124.98 | 2021-2024 | Brukinsa |
| Takeda Pharmaceuticals U.S.A., INC. | $117.29 | 2020 | |
| Astellas Pharma US INC | $105.43 | 2022-2024 | Xtandi |
| Pharmacyclics LLC, An Abbvie Company | $102.08 | 2021-2023 | Epkinly, Imbruvica |
| E.R. Squibb & Sons, L.L.C. | $99.26 | 2023-2025 | Opdivo, Opdualag |
| Puma Biotechnology, INC. | $89.77 | 2020-2024 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $88.92 | 2022-2024 | |
| Daiichi Sankyo INC. | $59.15 | 2024-2025 | Enhertu |
| Incyte Corporation | $58.79 | 2022-2023 | Pemazyre |
| Janssen Pharmaceuticals, INC | $57.72 | 2022-2025 | Tecvayli, Darzalex, Talvey |
| Jazz Pharmaceuticals INC. | $46.74 | 2021-2023 | |
| Exelixis INC. | $42.42 | 2019 | |
| Gilead Sciences, INC. | $35.86 | 2021-2025 | Trodelvy |
| Pharmaessentia USA Corporation | $32.22 | 2025 | Besremi |
| Depuy Synthes Sales INC. | $30.00 | 2019 | |
| Sobi, INC | $27.95 | 2022 | |
| Abbvie INC. | $26.91 | 2024 | |
| Taiho Oncology, INC. | $26.36 | 2024 | |
| Mirati Therapeutics, INC. | $25.90 | 2023 | Krazati |
| Stemline Therapeutics INC. | $23.88 | 2023 | Orserdu |
| Geron Corporation | $21.94 | 2025 | Rytelo |
| Bayer Healthcare Pharmaceuticals INC. | $19.24 | 2023 | |
| Genzyme Corporation | $18.40 | 2020 | |
| Beone Medicines USA, INC. | $18.31 | 2025 | Brukinsa |
| Karyopharm Therapeutics INC. | $17.84 | 2023 | Xpovio |
| Regeneron Healthcare Solutions, INC. | $15.19 | 2024 | Libtayo |
| Emd Serono, INC. | $15.11 | 2023 | Bavencio |
| Myriad Genetic Laboratories, INC. | $12.79 | 2022 | |
| Acrotech Biopharma INC. | $11.97 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kamran Shahid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.